Is Denifanstat Safer Than Isotretinoin?
Acne affects millions of people, and treatments like isotretinoin have been around for decades. But isotretinoin, often called Accutane, comes with serious side effects. These include dry skin, high cholesterol, liver issues, and even risks of birth defects if taken during pregnancy. Doctors require strict monitoring, like monthly blood tests, because of these dangers. Many patients look for safer options.
Enter denifanstat, a new drug developed by companies like Sagimet Biosciences and Ascletis. It targets fatty acid synthase, an enzyme linked to excess oil production in the skin that causes acne. Unlike isotretinoin, which is a powerful retinoid affecting the whole body, denifanstat focuses on this specific pathway. Recent studies show promise for treating moderate to severe acne.
In a Phase III trial in China, denifanstat beat placebo on all key measures of acne improvement. Patients saw fewer lesions and better skin after treatment. Safety stood out: all side effects tied to the drug were mild or moderate. No severe reactions, no serious events linked to it, and no one had to stop taking it due to problems. This trial wrapped up with strong results presented at a big dermatology conference in 2025.
Other early tests, like a Phase II study, also cut lesion counts after just 12 weeks. When combined with another drug for liver issues, denifanstat stayed well-tolerated with no safety red flags. These findings suggest it could be easier on the body than isotretinoin, which often causes tougher side effects.
Denifanstat is not approved everywhere yet. China regulators accepted it for review based on the Phase III data, a big step forward. Outside China, Sagimet is testing it more for acne and liver conditions. Direct head-to-head trials against isotretinoin are lacking so far. Still, the clean safety profile in large trials makes denifanstat look encouraging for those tired of isotretinoin’s risks.
Sources
https://markets.businessinsider.com/news/stocks/sagimet-biosciences-announces-positive-results-from-the-phase-1-pk-clinical-trial-of-denifanstat-and-resmetirom-combination-1035656325
https://www.tipranks.com/news/the-fly/sagimet-announces-results-from-phase-1-pk-trial-of-denifanstat-resmetirom-thefly
https://www.prnewswire.com/news-releases/ascletis-announces-china-national-medical-products-administration-acceptance-of-new-drug-application-for-denifanstat-asc40-a-first-in-class-fasn-inhibitor-for-acne-treatment-302637708.html
https://www.dermatologyadvisor.com/news/denifanstat-improves-lesion-count-moderate-severe-acne-vulgaris/
https://www.stocktitan.net/news/SGMT/sagimet-s-license-partner-ascletis-announced-acceptance-of-new-drug-my9wyvmm6620.html
https://www.quiverquant.com/news/Sagimet+Biosciences+Enters+License+Agreement+with+TAPI+for+Innovative+Forms+of+Resmetirom+in+Fixed-Dose+Combination+Development
